1. HOME
2. Research Insight
3. Danaher (US) and ZEISS Group (Germany) are Leading Players in the Live Cell Imaging Market

The global live cell imaging market is projected to reach USD 4.3 billion by 2028 from USD 2.7 billion in 2023, at a CAGR of 10.2% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by growing adoption of high-content screening techniques in drug discovery. Live cell imaging is an essential tool in high-content screening (HCS), allowing researchers to observe and track cellular responses in real-time. High-resolution imaging can provide valuable information on the structure and function of cells, as well as the effects of potential drug compounds.

The global market is a consolidated market, with Danaher (US), ZEISS Group (Germany), Thermo Fisher Scientific, Inc. (US), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer Inc. (US), and  Sartorius AG (Germany) together accounting for ~75–85% of the global market.

To know about the assumptions considered for the study download the pdf brochure

Danaher (US)

Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Its business consists of four segments: Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences business offers a broad range of research tools and provides solutions for five key subsegments: Flow Cytometry, Genomics, Lab Automation, Centrifugation, Particle Counting and Characterization, Mass Spectrometry, Microscopy, Industrial Filtration, and Genomic Consumables. Live cell imaging solutions fall under the Microscopy subsegment. The company's live cell imaging products are provided by two subsidiaries: Molecular Devices LLC (US) and Leica Microsystems CMS GmbH (Germany).

In 2005, Danaher acquired Leica Microsystems and its subsidiaries. Leica Microsystems is a provider of microscopy, camera, and software solutions for imaging and analysis of macro, micro, and nanostructures. In 2010, Danaher also acquired Molecular Devices (US), a provider of high-performance bioanalytical measurement systems, software, and consumables for life science research and pharmaceutical and biotherapeutic development.

The company operates through facilities in over 60 countries, including 244 significant ministrative, sales, research & development, manufacturing, and distribution facilities, of which 90 facilities are in the US in over 20 states, and 154 are located outside the US. Some of its major Life Sciences subsidiaries are Molecular Devices, LLC (US), Beckman Coulter Life Sciences (US), and Leica Microsystems (Germany).

ZEISS Group (Germany)

ZEISS Group operates in the fields of optics and optoelectronics. Carl Zeiss AG is the strategic management holding company that manages the ZEISS Group. The company operates its business through five segments: Semiconductor Manufacturing Technology, Industrial Quality and Research, Medical Technology, Consumer Markets, and Others. The Industrial Quality and Research segment provides industrial quality solutions and research microscopy solutions. The company operates in the live cell imaging market through its Industrial Quality and Research segment.

The company has operations in more than 50 countries and has more than 60 sales and service locations. Geographically, the company operates in the Europe, Middle East, and Africa (EMEA); the Americas; and the APAC regions. The company’s notable subsidiaries include Carl Zeiss Microscopy, LLC (US), Carl Zeiss Canada Ltd., Carl Zeiss Microscopy GmbH (Germany), Carl Zeiss Microscopy Limited (UK), and Carl Zeiss (Shanghai) Co., Ltd, among others.

Sartorius AG (Germany)

Sartorius AG is an international pharmaceutical and laboratory equipment supplier. The company has two primary business segments: Bioprocess Solutions and Lab Products & Services. The Lab Products & Services division offers laboratory balances, pipettes, and laboratory consumables, among others. Live cell imaging products are offered mainly by the Lab Products & Services division of the company. In March 2017, Sartorius acquired Essen Bioscience, Inc. (US), a company that develops and markets innovative real-time live cell imaging and analysis systems for drug research.

The company has a widespread presence across the Americas, Europe, Asia Pacific, the Middle East, and Africa, and has subsidiaries in more than 30 countries. Some of the company’s subsidiaries include Sartorius Stedim Biotech S.A. (France), Sartorius Stedim North America Inc. (US), Sartorius Stedim UK Ltd., Sartorius Stedim Belgium N.V., and Sartorius Stedim India Pvt. Ltd.

Related Reports:

Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services), Application (Cell Biology, Stem Cells, Drug Discovery), Technology (Time-lapse Microscopy, FRET, FRAP, HCS), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]